10x fund lp - by 10x fund lp investment history in Galectin therapeutics inc

Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 570000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2010-05-10 exercise price 0.5 has valueitem expiration due date 2015-05-10 underlying security shares 570000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 310000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2010-04-30 exercise price 0.5 has valueitem expiration due date 2015-04-30 underlying security shares 310000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 335000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2010-03-08 exercise price 0.5 has valueitem expiration due date 2015-03-08 underlying security shares 335000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 325000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2010-01-29 exercise price 0.5 has valueitem expiration due date 2015-01-29 underlying security shares 325000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 325000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-12-08 exercise price 0.5 has valueitem expiration due date 2014-12-08 underlying security shares 325000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 310000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-11-03 exercise price 0.5 has valueitem expiration due date 2014-11-03 underlying security shares 310000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 235000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-09-30 exercise price 0.5 has valueitem expiration due date 2014-09-30 underlying security shares 235000 underlying security title Common Stock

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 206724 shares at $0.9202 remaining shares owned 9069422

Common Stock Galectin Therapeutics Inc Galt Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f4 dividends received on series b convertible preferred stock owned by 10x fund, lp.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000009.txt Sec File: edgar/data/1457247/0001453356-11-000009-index.htm

2011-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 2410000 shares at $0.5 remaining shares owned 8862698

Common Stock Galectin Therapeutics Inc Galt Transaction code: X Exercise of in-the-money or at-the-money derivatives securities (usually options)

f1 on september 30, 2011, 10x fund, lp exercised 2,410,000 class a-1 warrants, and as a result acquired 2,410,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,205,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 90000 shares remaining shares owned 235000

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-09-30 exercise price 0.5 has valueitem expiration due date 2014-09-30 underlying security shares 90000 underlying security title Common Stock

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 300000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-08-12 exercise price 0.5 has valueitem expiration due date 2014-08-12 underlying security shares 300000 underlying security title Common Stock

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 500000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-06-30 exercise price 0.5 has valueitem expiration due date 2014-06-30 underlying security shares 500000 underlying security title Common Stock

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 900000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-05-13 exercise price 0.5 has valueitem expiration due date 2014-05-13 underlying security shares 900000 underlying security title Common Stock

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 1800000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-02-12 exercise price 0.5 has valueitem expiration due date 2014-02-12 underlying security shares 1800000 underlying security title Common Stock

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.


Filed on 2011-07-27 by 10x Capital Management, Llc SEC CIK 1457247 Form 4/a

Accession 0001453356-11-000008.txt Sec File: edgar/data/1457247/0001453356-11-000008-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 3590000 shares at $0.5 remaining shares owned 6452698

Common Stock Galectin Therapeutics Inc Galt Transaction code: X Exercise of in-the-money or at-the-money derivatives securities (usually options)

f1 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.50 per share. the aggregate exercise price was $1,795,000.
f4 this amendment is being filed to correct the exercise price of the warrant exercise reported in table ii of the the original form 4, and the purchase price of the securities acquired upon exercise of said warrants in table i of the original form 4.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 90000 shares remaining shares owned 235000

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-09-30 exercise price 0.05 has valueitem expiration due date 2014-09-30 underlying security shares 90000 underlying security title Common Stock

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 300000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-08-12 exercise price 0.05 has valueitem expiration due date 2014-08-12 underlying security shares 300000 underlying security title Common Stock

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 500000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-06-30 exercise price 0.05 has valueitem expiration due date 2014-06-30 underlying security shares 500000 underlying security title Common Stock

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 900000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-05-13 exercise price 0.05 has valueitem expiration due date 2014-05-13 underlying security shares 900000 underlying security title Common Stock

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc sold 1800000 shares remaining shares owned 0

Class A-1 Warrant Galectin Therapeutics Inc Galt exercise date 2009-02-12 exercise price 0.05 has valueitem expiration due date 2014-02-12 underlying security shares 1800000 underlying security title Common Stock

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 3590000 shares at $1.22 remaining shares owned 6452698

Common Stock Galectin Therapeutics Inc Galt Transaction code: X Exercise of in-the-money or at-the-money derivatives securities (usually options)

f4 on june 30, 2011, 10x fund, lp exercised 3,590,000 class a-1 warrants, and as a result acquired 3,590,000 shares of common stock of the issuer. the warrants were exercisable at $0.05 per share. the aggregate exercise price was $1,795,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 380475 shares at $1.22 remaining shares owned 2862698

Common Stock Galectin Therapeutics Inc Galt Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f1 received as a divdend on series b convertible preferred stock owned by 10x fund, lp
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2011-07-05 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-11-000005.txt Sec File: edgar/data/1457247/0001453356-11-000005-index.htm

2011-03-31 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Galectin Therapeutics Inc bought 380475 shares at $1.04 remaining shares owned 2482223

Common Stock Galectin Therapeutics Inc Galt Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f1 received as a divdend on series b convertible preferred stock owned by 10x fund, lp
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.